1 |
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B. 3rd. and Stockwell, B. R. 2012. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072.
DOI
|
2 |
Sun, X. X., Challagundla, K. B. and Dai, M. S. 2012. Positive regulation of p53 stability and activity by the deubiquitinating enzyme otubain 1. EMBO J. 31, 576-592.
DOI
|
3 |
Swatek, K. N. and Komander, D. 2016. Ubiquitin modifications. Cell Res. 26, 399-422.
DOI
|
4 |
Wang, Y., Zhou, X., Xu, M., Weng, W., Zhang, Q., Yang, Y., Wei, P. and Du, X. 2016. OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer. Oncotarget 7, 36681-36697.
DOI
|
5 |
Wiener, R., Zhang, X., Wang, T. and Wolberger, C. 2012. The mechanism of OTUB1-mediated inhibition of ubiquitination. Nature 483, 618-622.
DOI
|
6 |
Xu, L., Li, J., Bao, Z., Xu, P., Chang, H., Wu, J., Bei, Y., Xia, L., Wu, P., Yan, K., Lu, B. and Cui, G. 2017. Silencing of OTUB1 inhibits migration of human glioma cells in vitro. Neuropathology 37, 217-226.
DOI
|
7 |
Hao, M., Weng, X., Wang, Y., Sun, X., Yan, T., Li, Y., Hou, L., Meng, X. and Wang, J. 2018. Targeting CXCR7 improves the efficacy of breast cancer patients with tamoxifen therapy. Biochem. Pharmacol. 147, 128-140.
DOI
|
8 |
Herhaus, L., Al-Salihi, M., Macartney, T., Weidlich, S. and Sapkota, G. P. 2013. OTUB1 enhances TGFbeta signalling by inhibiting the ubiquitylation and degradation of active SMAD2/3. Nat. Commun. 4, 2519-2531.
DOI
|
9 |
Herhaus, L., Perez-Oliva, A. B., Cozza, G., Gourlay, R., Weidlich, S., Campbell, D. G., Pinna, L. A. and Sapkota, G. P. 2015. Casein kinase 2 (CK2) phosphorylates the deubiquitylase OTUB1 at ser16 to trigger its nuclear localization. Sci. Signal. 8, ra35.
DOI
|
10 |
Iglesias-Gato, D., Chuan, Y. C., Jiang, N., Svensson, C., Bao, J., Paul, I., Egevad, L., Kessler, B. M., Wikstrom, P., Niu, Y. and Flores-Morales, A. 2015. OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo. Mol. Cancer 14, 8-21.
DOI
|
11 |
Jensen, D. E., Proctor, M., Marquis, S. T., Gardner, H. P., Ha, S. I., Chodosh, L. A., Ishov, A. M., Tommerup, N., Vissing, H., Sekido, Y., Minna, J., Borodovsky, A., Schultz, D. C., Wilkinson, K. D., Maul, G. G., Barlev, N., Berger, S. L., Prendergast, G. C. and Rauscher, F. J. 3rd. 1998. BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097-1112.
DOI
|
12 |
Zhou, H., Liu, Y., Zhu, R., Ding, F., Cao, X., Lin, D. and Liu, Z. 2018. OTUB1 promotes esophageal squamous cell carcinoma metastasis through modulating Snail stability. Oncogene 37, 3356-3368.
DOI
|
13 |
Xu, L., Lubkov, V., Taylor, L. J. and Bar-Sagi, D. 2010. Feedback regulation of Ras signaling by Rabex-5-mediated ubiquitination. Curr. Biol. 20, 1372-1377.
DOI
|
14 |
Yuan, L., Yuan, P., Yuan, H., Wang, Z., Run, Z., Chen, G., Zhao, P. and Xu, B. 2017. Mir-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1. Am. J. Cancer Res. 7, 159-172.
|
15 |
Zhao, L., Wang, X., Yu, Y., Deng, L., Chen, L., Peng, X., Jiao, C., Gao, G., Tan, X., Pan, W., Ge, X. and Wang, P. 2018. OTUB1 protein suppresses mTOR complex 1 (mTORC1) activity by deubiquitinating the mTORC1 inhibitor DEPTOR. J. Biol. Chem. 293, 4883-4892.
DOI
|
16 |
Pinto-Fernandez, A. and Kessler, B. M. 2016. Dubbing cancer: Deubiquitylating enzymes involved in epigenetics, DNA damage and the cell cycle as therapeutic targets. Front. Genet. 7, 133-145.
|
17 |
Juang, Y. C., Landry, M. C., Sanches, M., Vittal, V., Leung, C. C., Ceccarelli, D. F., Mateo, A. R., Pruneda, J. N., Mao, D. Y., Szilard, R. K., Orlicky, S., Munro, M., Brzovic, P. S., Klevit, R. E., Sicheri, F. and Durocher, D. 2012. OTUB1 co-opts Lys48-linked ubiquitin recognition to suppress E2 enzyme function. Mol. Cell 45, 384-397.
DOI
|
18 |
Zhou, Y., Jia, Q., Meng, X., Chen, D. and Zhu, B. 2019. ERRalpha regulates OTUB1 expression to promote colorectal cancer cell migration. J. Cancer 10, 5812-5819.
DOI
|
19 |
Nicastro, G., Menon, R. P., Masino, L., Knowles, P. P., McDonald, N. Q. and Pastore, A. 2005. The solution structure of the Josephin domain of ataxin-3: Structural determinants for molecular recognition. Proc. Natl. Acad. Sci. USA. 102, 10493-10498.
DOI
|
20 |
Nijman, S. M., Luna-Vargas, M. P., Velds, A., Brummelkamp, T. R., Dirac, A. M., Sixma, T. K. and Bernards, R. 2005. A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786.
DOI
|
21 |
Quesada, V., Ordonez, G. R., Sanchez, L. M., Puente, X. S. and Lopez-Otin, C. 2009. The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res. 37, D239-243.
DOI
|
22 |
Reyes-Turcu, F. E., Ventii, K. H. and Wilkinson, K. D. 2009. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78, 363-397.
DOI
|
23 |
Sato, Y., Yoshikawa, A., Yamagata, A., Mimura, H., Yamashita, M., Ookata, K., Nureki, O., Iwai, K., Komada, M. and Fukai, S. 2008. Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains. Nature 455, 358-362.
DOI
|
24 |
Ernst, A., Avvakumov, G., Tong, J., Fan, Y., Zhao, Y., Alberts, P., Persaud, A., Walker, J. R., Neculai, A. M., Neculai, D., Vorobyov, A., Garg, P., Beatty, L., Chan, P. K., Juang, Y. C., Landry, M. C., Yeh, C., Zeqiraj, E., Karamboulas, K., Allali-Hassani, A., Vedadi, M., Tyers, M., Moffat, J., Sicheri, F., Pelletier, L., Durocher, D., Raught, B., Rotin, D., Yang, J., Moran, M. F., Dhe-Paganon, S. and Sidhu, S. S. 2013. A strategy for modulation of enzymes in the ubiquitin system. Science 339, 590-595.
DOI
|
25 |
Sheng, C., Dong, G., Miao, Z., Zhang, W. and Wang, W. 2015. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Chem. Soc. Rev. 44, 8238-8259.
DOI
|
26 |
Stanisic, V., Malovannaya, A., Qin, J., Lonard, D. M. and O'Malley, B. W. 2009. OTU domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity. J. Biol. Chem. 284, 16135-16145.
DOI
|
27 |
Abdul Rehman, S. A., Kristariyanto, Y. A., Choi, S. Y., Nkosi, P. J., Weidlich, S., Labib, K., Hofmann, K. and Kulathu, Y. 2016. MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol. Cell 63, 146-155.
DOI
|
28 |
Altun, M., Kramer, H. B., Willems, L. I., McDermott, J. L., Leach, C. A., Goldenberg, S. J., Kumar, K. G., Konietzny, R., Fischer, R., Kogan, E., Mackeen, M. M., McGouran, J., Khoronenkova, S. V., Parsons, J. L., Dianov, G. L., Nicholson, B. and Kessler, B. M. 2011. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem. Biol. 18, 1401-1412.
DOI
|
29 |
Arkin, M. R., Tang, Y. and Wells, J. A. 2014. Small-molecule inhibitors of protein-protein interactions: Progressing toward the reality. Chem. Biol. 21, 1102-1114.
DOI
|
30 |
Edelmann, M. J., Kramer, H. B., Altun, M. and Kessler, B. M. 2010. Post-translational modification of the deubiquitinating enzyme otubain 1 modulates active rhoa levels and susceptibility to yersinia invasion. FEBS J. 277, 2515-2530.
DOI
|
31 |
Fagerberg, L., Hallstrom, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., Asplund, A., Sjostedt, E., Lundberg, E., Szigyarto, C. A., Skogs, M., Takanen, J. O., Berling, H., Tegel, H., Mulder, J., Nilsson, P., Schwenk, J. M., Lindskog, C., Danielsson, F., Mardinoglu, A., Sivertsson, A., von Feilitzen, K., Forsberg, M., Zwahlen, M., Olsson, I., Navani, S., Huss, M., Nielsen, J., Ponten, F. and Uhlen, M. 2014. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibodybased proteomics. Mol. Cell. Proteomics 13, 397-406.
DOI
|
32 |
Finley, D., Ciechanover, A. and Varshavsky, A. 2004. Ubiquitin as a central cellular regulator. Cell 116, S29-32.
DOI
|
33 |
Gao, S., Alarcon, C., Sapkota, G., Rahman, S., Chen, P. Y., Goerner, N., Macias, M. J., Erdjument-Bromage, H., Tempst, P. and Massague, J. 2009. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol. Cell 36, 457-468.
DOI
|
34 |
Goncharov, T., Niessen, K., de Almagro, M. C., Izrael-Tomasevic, A., Fedorova, A. V., Varfolomeev, E., Arnott, D., Deshayes, K., Kirkpatrick, D. S. and Vucic, D. 2013. OTUB1 modulates c-IAP1 stability to regulate signalling pathways. EMBO J. 32, 1103-1114.
DOI
|
35 |
Koulich, E., Li, X. and DeMartino, G. N. 2008. Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. Mol. Biol. Cell 19, 1072-1082.
DOI
|
36 |
Karunarathna, U., Kongsema, M., Zona, S., Gong, C., Cabrera, E., Gomes, A. R., Man, E. P., Khongkow, P., Tsang, J. W., Khoo, U. S., Medema, R. H., Freire, R. and Lam, E. W. 2016. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene 35, 1433-1444.
DOI
|
37 |
Komander, D., Clague, M. J. and Urbe, S. 2009. Breaking the chains: Structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 10, 550-563.
DOI
|
38 |
Komander, D. and Rape, M. 2012. The ubiquitin code. Annu. Rev. Biochem. 81, 203-229.
DOI
|
39 |
Kulathu, Y. and Komander, D. 2012. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat. Rev. Mol. Cell Biol. 13, 508-523.
DOI
|
40 |
Li, Y., Sun, X. X., Elferich, J., Shinde, U., David, L. L. and Dai, M. S. 2014. Monoubiquitination is critical for ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 (Otub1) to suppress UbcH5 enzyme and stabilize p53 protein. J. Biol. Chem. 289, 5097-5108.
DOI
|
41 |
Liu, T., Jiang, L., Tavana, O. and Gu, W. 2019. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7 A11. Cancer Res. 79, 1913-1924.
DOI
|
42 |
Makarova, K. S., Aravind, L. and Koonin, E. V. 2000. A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and chlamydia pneumoniae. Trends Biochem. Sci. 25, 50-52.
DOI
|
43 |
Chen, Y., Wang, Y. G., Li, Y., Sun, X. X. and Dai, M. S. 2017. Otub1 stabilizes MDMX and promotes its proapoptotic function at the mitochondria. Oncotarget 8, 11053-11062.
DOI
|
44 |
Nakada, S., Tai, I., Panier, S., Al-Hakim, A., Iemura, S., Juang, Y. C., O'Donnell, L., Kumakubo, A., Munro, M., Sicheri, F., Gingras, A. C., Natsume, T., Suda, T. and Durocher, D. 2010. Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature 466, 941-946.
DOI
|
45 |
Arnst, J. L., Davies, C. W., Raja, S. M., Das, C. and Natarajan, A. 2013. High-throughput compatible fluorescence resonance energy transfer-based assay to identify small molecule inhibitors of amsh deubiquitinase activity. Anal. Biochem. 440, 71-77.
DOI
|
46 |
Baietti, M. F., Simicek, M., Abbasi Asbagh, L., Radaelli, E., Lievens, S., Crowther, J., Steklov, M., Aushev, V. N., Martinez Garcia, D., Tavernier, J. and Sablina, A. A. 2016. OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination. EMBO Mol. Med. 8, 288-303.
DOI
|
47 |
Balakirev, M. Y., Tcherniuk, S. O., Jaquinod, M. and Chroboczek, J. 2003. Otubains: A new family of cysteine proteases in the ubiquitin pathway. EMBO Rep. 4, 517-522.
DOI
|
48 |
Chen, J., Dexheimer, T. S., Ai, Y., Liang, Q., Villamil, M. A., Inglese, J., Maloney, D. J., Jadhav, A., Simeonov, A. and Zhuang, Z. 2011. Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem. Biol. 18, 1390-1400.
DOI
|
49 |
D'Arcy, P., Wang, X. and Linder, S. 2015. Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol. Ther. 147, 32-54.
DOI
|
50 |
Deshaies, R. J. and Joazeiro, C. A. 2009. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399-434.
DOI
|